As per sources, Bharat Biotech’s Covaxin has shown up to 77.8 per cent efficacy in phase 3 trial data in review by subject expert committee (SEC).The Subject Expert Committee (SEC) today under the drug regulator discussed and reviewied the Phase III data of Bharat Biotech's Covaxin on Tuesday.
The meeting was held before Bharat Biotech's 'pre-submission' meeting on Wednesday with the World Health Organization (WHO), for the approval for their COVID vaccine 'Covaxin'.
The Hyderabad-based COVID vaccine manufacturing company Bharat Biotech submitted data from the Phase III clinical trials of Covaxin to the Drugs Controller General of India (DCGI) over the weekend, according to government sources.
Bharat Biotech's Covaxin is one of the three vaccines which are currently being used in India. The phase III data of its vaccine have been questioned various times and that is what makes the data crucial which will ascertain the efficacy of the vaccine.
The company has developed the vaccine in association with the Indian Council of Medical Research (ICMR).